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Abstract
Background: Post-transplant anaemia remains a common problem after kidney transplantation, with an
incidence ranging from nearly 80% at day 0 to about 25% at 1 year. It has been associated with poor graft
outcome, and recently has also been shown to be associated with increased mortality.
Our transplant unit routinely administers oral iron supplements to renal transplant recipients but this is
frequently accompanied by side effects, mainly gastrointestinal intolerance. Intravenous iron is frequently
administered to dialysis patients and we sought to investigate this mode of administration in transplant
recipients after noticing less anaemia in several patients who had received intravenous iron just prior to
being called in for transplantation.
Methods: This study is a single-centre, prospective, open-label, randomised, controlled trial of oral versus
intravenous iron supplements in renal transplant recipients and aims to recruit approximately 100 patients
over a 12-month period. Patients will be randomised to receive a single dose of 500 mg iron polymaltose
(intravenous iron group) or 2 ferrous sulphate slow-release tablets daily (oral iron group). The primary
outcome is time to normalisation of haemoglobin post-transplant. Prospective power calculations have
indicated that a minimum of 48 patients in each group would have to be followed up for 3 months in order
to have a 90% probability of detecting a halving of the time to correction of haemoglobin levels to ≥110
g/l in iron-treated patients, assuming an α of 0.05. All eligible adult patients undergoing renal
transplantation at the Princess Alexandra Hospital will be offered participation in the trial. Exclusion
criteria will include iron overload (transferrin saturation >50% or ferritin >800 μg/l), or previous
intolerance of either oral or intravenous iron supplements.
Discussion: If the trial shows a reduction in the time to correction of anaemia with intravenous iron or
less side effects than oral iron, then intravenous iron may become the standard of treatment in this patient
group.
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Background
Post-transplant anaemia (PTA) remains a common prob-
lem after kidney transplantation, with an incidence rang-
ing from nearly 80% at day 0 to about 25% at 1 year [1-
4]. It has been associated with poor graft outcome, and
recently has also been shown to be associated with
increased mortality [5]
PTA may occur at any time after renal transplantation.
Early PTA (post surgery until 3 months) is most likely to
be related to pre-transplant anaemia, the surgery itself,
iron deficiency, immunosuppression and infection [6,7].
PTA is more likely to be related to consequences of long-
term immunosuppression or a failing graft. All the large
scale studies to date have focused mainly on late PTA
[4,6,7], and there is a lack of studies looking at the man-
agement of early PTA, in particular, the optimal manage-
ment of iron deficiency.
Our unit routinely administers oral ferrous sulphate to all
post transplant patients, however this is not without prob-
lems including gastrointestinal intolerance, and interfer-
ence with the absorption of immunosuppressant
medications by leading to significant constipation.
Recently, we have observed that several dialysis patients
serendipitously given intravenous iron for treatment of
iron deficiency anaemia immediately prior to transplanta-
tion, have had better Hb levels in the post-transplant
period, without needing oral iron supplementation. In a
retrospective case series, Gillespie and Symonds used
intravenous ferrous gluconate to treat 15 paediatric and
young adult renal transplant recipients and found that
doses of up to 250 mg induced a statistically significant
increase in mean haemoglobin levels. There were only 4
adverse events reported in 3 patients, all self limiting and
none life threatening [8]. However, there are no trials to
date comparing the efficacy of intravenous versus oral
iron replacement.
We surmise that giving a single dose of intravenous iron
(as ferrous gluconate – Ferrosig®) may be superior to a
protracted course of oral iron.
The aim of the study therefore, is to compare the time to
normalisation of Hb post-transplant in patients given a
single dose of IV iron as compared with oral iron.
Methods
Patients
All adult patients receiving a renal transplant at the Prin-
cess Alexandra Hospital will be invited to participate in
the study. Informed consent will be obtained from all par-
ticipants. The study protocol has been approved by the
Princess Alexandra Hospital Human Research Ethics
Committee (HREC), approval number 2007/142.
Inclusion criteria will include new living-donor or
deceased-donor renal transplant recipients aged 18 years
or over who are able to give written informed consent.
Exclusion criteria will include iron overload (transferrin
saturation >50% or ferritin >800 μg/l), women lactating,
pregnant or of child-bearing potential not using a reliable
contraceptive method, patients with a history of psycho-
logical illness or condition which interferes with their
ability to understand or comply with the requirements of
the study, patients who have received a new investiga-
tional drug within the last 4 weeks, and intolerance of
intravenous or oral iron supplements.
Design
This is an open-label, randomised, controlled clinical trial
in which the primary outcome measure will be the mean
t i m e  t o  r e s o l u t i o n  o f  P T A  ( d e f i n e d  a s  H b  ≥110 g/l).
Patients meeting the inclusion criteria and consenting to
participate in the study will be randomly allocated in a 1:1
ratio to either (a) oral iron (ferrous sulphate slow-release
2 tablets mane – the most common current practice in the
transplant unit) or (b) intravenous iron polymaltose as a
500 mg single dose given within the first 5 days after trans-
plantation. Randomisation will occur by the use of
sequentially numbered, sealed, opaque envelopes with
stratification for calcineurin inhibitor type (cyclosporin or
tacrolimus).
Immunosuppressive therapy will be managed according
to the unit's standard protocols. Patients will have blood
tests checked as per the unit's follow up protocol for
recent transplant recipients. We will collect full blood
count, renal function, and calcineurin inhibitor trough
levels on a weekly basis, as well as iron studies, B12, and
folate at one monthly intervals.
Power and statistical analysis
Prospective power calculations have indicated that a min-
imum of 48 patients in each group would have to be fol-
lowed up for 3 months in order to have a 90% probability
of detecting a halving of the time to correction of haemo-
globin levels to ≥110 g/l in iron-treated patients, assum-
ing an α of 0.05.
Adverse events during the investigation
Each patient will be observed closely during the period of
the study looking for adverse events and if any occur they
will be documented on a Case Report Form. Any signifi-
cant adverse events will also be notified to the P.A. Hospi-
tal Research Ethics Committee.Publish with BioMed Central    and   every 
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Gastrointestinal adverse effects will be defined as the
onset of nausea, vomiting, abdominal cramping or diar-
rhoea. Infusion related reactions will be described as self-
limiting flushing sweating, chills, myalgias, arthralgias,
bronchospasm and chest pain occurring at the time of the
infusion. All infectious episodes and the results of subse-
quent microbiological investigation will be recorded dur-
ing the study period.
Discussion
As far as the authors are aware, this will be the first ran-
domised trial of intravenous versus oral iron supplemen-
tation for PTA in kidney transplantation. If the trial shows
a reduction in the time to correction of anaemia with
intravenous iron or alternatively if there is no difference
but fewer side effects than oral iron, then intravenous iron
may become the preferred treatment in this patient group.
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